



## Scottish biotechnology companies to chair expert panel session at *Pharma Integrates*

Edinburgh, Scotland. 1 November 2016.

Dr Tina Flatau, Managing Director of innovative Edinburgh-based biotechnology companies OncoBioPharm Ltd and MedAnnex Ltd, has been invited to chair a panel session of experts at the 2016 *Pharma Integrates* conference at London's Grange City Hotel later this month.

The conference, which is sponsored by Catalent, Pfizer and Patheon, is now in its fifth year. This year's focus is on the strategic issues facing the drug manufacturing industry. Speakers will include Prof John Bell and Prof Chas Bountra (University of Oxford), Prof Sue Hill (Chief Scientific Officer, NHS England) and Prof Guido Rasi (Executive Director, European Medicines Agency).



**Dr Tina Flatau**

Dr Flatau, who joined sister companies OncoBioPharm and MedAnnex as MD in January 2016, said: "I'm delighted to be involved with Pharma Integrates. High-profile, peer-to-peer events like this offer excellent opportunities to connect and debate with industry colleagues and key opinion leaders. Scotland has a well-deserved international reputation for innovation in many fields, and as MedAnnex and OncoBioPharm continue to develop our novel antibodies for the treatment of various serious conditions, it's vital that we remain up-to-date with the issues that are shaping the future of our industry."

Dr Flatau will chair a discussion entitled *Achieving Patient Compliance* on Wednesday 16 November, focusing on getting the right dose to the right place at the right time. More details can be found at [www.pharma-integrates.com](http://www.pharma-integrates.com).

### **About OncoBioPharm Ltd**

OncoBioPharm ([www.oncobiopharm.com](http://www.oncobiopharm.com)) is an Edinburgh-based biotechnology company developing therapeutic antibodies that target novel pathways associated with cancer cell growth and spread, with the aim of extending and improving the lives of people with cancer. The company's lead product Tensinomab<sup>®</sup> has been shown to block cancer cell growth, invasion and metastasis in a variety of experimental models, and has the potential to become a powerful new treatment for cancer and other serious conditions.

### **About MedAnnex Ltd**

MedAnnex ([www.medannex.org](http://www.medannex.org)) is an Edinburgh-based biotechnology company developing novel treatments for autoimmune diseases. The company's lead product Annexuzlimab<sup>®</sup> targets annexin-1, a key factor in the immune system, which is over-expressed in people with autoimmune conditions. Annexuzlimab has shown impressive results in experimental models of several major autoimmune diseases, including multiple sclerosis and rheumatoid arthritis.